Management of Non-Provoked Proximal DVT and Bilateral PE on Apixaban
Initial Anticoagulation Regimen
- The American College of Chest Physicians recommends apixaban as an appropriate choice for initial anticoagulation, administered at 10 mg twice daily for the first 7 days, followed by 5 mg twice daily for at least 3-6 months 1
- Apixaban has been shown to be non-inferior to conventional therapy for preventing recurrent VTE or VTE-related death, with a lower major bleeding risk of 0.6% compared to 1.8% with conventional therapy 2
Duration of Therapy
- The American College of Chest Physicians suggests extended anticoagulation therapy over limiting treatment to 3 months for unprovoked proximal DVT and PE, especially with low or moderate bleeding risk 3, 4
- Extended therapy is justified due to the high risk of recurrence after unprovoked VTE, with a significant reduction in recurrence risk 4
Monitoring and Follow-up
- Routine re-evaluation should be performed 3-6 months after the acute PE event, and regular intervals thereafter to reassess drug tolerance, adherence, hepatic and renal function, and bleeding risk 5
- No routine laboratory monitoring of anticoagulant effect is required for apixaban, unlike warfarin 1, 2
Dose Considerations for Extended Therapy
- After completing the initial 6 months of treatment, consider continuing standard-dose apixaban or switching to lower-dose apixaban for secondary prevention, with similar efficacy and potentially lower bleeding risk 6
Special Considerations
- Apixaban should be avoided in patients with severe renal impairment or hepatic impairment due to increased risk of bleeding 2
Management of Recurrent VTE
- If recurrent VTE occurs while on apixaban, consider switching to LMWH, evaluating for treatment compliance, or assessing for other hypercoagulable conditions that may require alternative management 7, 4